IHS Chemical Week

EnviroTech :: Biotech

U.S. Firm Acquires Novozymes Biopharma Sweden

10:16 AM MDT | November 3, 2011 | Deepti Ramesh

Biopharmaceutical company Repligen (Waltham, MA) says it has signed a definitive agreement to acquire Novozymes Biopharma Sweden (Lund, Sweden), a business of Novozymes (Bagsvaerd, Denmark), for €17 million ($24 million) and future potential milestone payments of €4 million. The acquisition will help Repligen to become a leading supplier of products for manufacturing biologic drugs. The transaction is expected to be finalized during the fourth quarter of 2011. The combined company is expected to generate total sales of about $50 million in fiscal year...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa